Literature DB >> 29617671

Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo.

Giorgia Rota1, Charlène Niogret1, Anh Thu Dang1, Cristina Ramon Barros1, Nicolas Pierre Fonta2, Francesca Alfei3, Leonor Morgado1, Dietmar Zehn3, Walter Birchmeier4, Eric Vivier5, Greta Guarda6.   

Abstract

In chronic infection and cancer, T cells acquire a dysfunctional state characterized by the expression of inhibitory receptors. In vitro studies implicated the phosphatase Shp-2 downstream of these receptors, including PD-1. However, whether Shp-2 is responsible in vivo for such dysfunctional responses remains elusive. To address this, we generated T cell-specific Shp-2-deficient mice. These mice did not show differences in controlling chronic viral infections. In this context, Shp-2-deleted CD8+ T lymphocytes expanded moderately better but were less polyfunctional than control cells. Mice with Shp-2-deficient T cells also showed no significant improvement in controlling immunogenic tumors and responded similarly to controls to α-PD-1 treatment. We therefore showed that Shp-2 is dispensable in T cells for globally establishing exhaustion and for PD-1 signaling in vivo. These results reveal the existence of redundant mechanisms downstream of inhibitory receptors and represent the foundation for defining these relevant molecular events.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PD-1; Ptpn11; Shp-2; T cell exhaustion; cancer; checkpoint therapy; chronic infection; inhibitory receptors

Mesh:

Substances:

Year:  2018        PMID: 29617671     DOI: 10.1016/j.celrep.2018.03.026

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  41 in total

Review 1.  Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies.

Authors:  Yara Abdou; Manu Pandey; Maithreyi Sarma; Shrunjal Shah; Jeffrey Baron; Marc S Ernstoff
Journal:  Br J Clin Pharmacol       Date:  2020-05-12       Impact factor: 4.335

2.  PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells.

Authors:  Young-Ho Lee; Hyeong Ji Lee; Hyung Cheol Kim; Yujean Lee; Su Kyung Nam; Cedric Hupperetz; Jennifer S Y Ma; Xinxin Wang; Oded Singer; Won Seog Kim; Seok Jin Kim; Youngil Koh; Inkyung Jung; Chan Hyuk Kim
Journal:  Mol Ther       Date:  2021-10-08       Impact factor: 11.454

Review 3.  Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity.

Authors:  Pooja Gupta; Tavneet Kaur Makkar; Lavisha Goel; Monika Pahuja
Journal:  Immunol Res       Date:  2022-07-20       Impact factor: 4.505

Review 4.  Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors.

Authors:  Diwakar Davar; Hassane M Zarour
Journal:  Methods Mol Biol       Date:  2020

Review 5.  Recent advances on T-cell exhaustion in malaria infection.

Authors:  Esaki M Shankar; R Vignesh; A P Dash
Journal:  Med Microbiol Immunol       Date:  2018-06-23       Impact factor: 3.402

Review 6.  T follicular helper cells in germinal center B cell selection and lymphomagenesis.

Authors:  Michelle A Mintz; Jason G Cyster
Journal:  Immunol Rev       Date:  2020-05-15       Impact factor: 12.988

7.  Transmembrane adaptor protein PAG is a mediator of PD-1 inhibitory signaling in human T cells.

Authors:  Marianne Strazza; Inbar Azoulay-Alfaguter; Michael Peled; Kieran Adam; Adam Mor
Journal:  Commun Biol       Date:  2021-06-03

Review 8.  The Role of Programmed Death-1 in Type 1 Diabetes.

Authors:  Brian T Fife; Tijana Martinov; Christopher G Tucker; Alexander J Dwyer
Journal:  Curr Diab Rep       Date:  2021-05-06       Impact factor: 5.430

9.  Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention.

Authors:  Xuefei Zhou; Xiangrui Liu; Leaf Huang
Journal:  Adv Funct Mater       Date:  2020-11-10       Impact factor: 18.808

Review 10.  Putting the brakes on phagocytosis: "don't-eat-me" signaling in physiology and disease.

Authors:  Shannon M Kelley; Kodi S Ravichandran
Journal:  EMBO Rep       Date:  2021-05-27       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.